We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Immunochemistry Analyzer Suitable for Low- to Mid-Volume Labs

By Labmedica staff writers
Posted on 22 Apr 2008
A new immunochemistry analyzer has been introduced, which was designed for labs that typically perform less than 200 immunoassay tests per day. More...
The instrument addresses many of the workflow challenges common in today's laboratories.

Called the Architect i1000SR analyzer, the new instrument enhances workflow and boosts laboratory productivity. Developed by Abbott (Abbott Park, IL, USA), the analyzer expands the Architect family of diagnostics instrument systems for clinical laboratories. The Architect i1000SR provides continuous access to reagents and samples while the instrument is running, enhancing laboratory productivity. Additionally, a wide test menu, user-friendly software, and low maintenance make it easy to train new laboratory personnel on the instrument's operation.

The Architect i1000SR analyzer can process up to 100 tests per hour. The instrument accommodates 65 patient samples and has the capability to prioritize emergency test results and turn them around in less than 16 minutes.

"Because time and ease of use are so critical in the testing environment, Abbott worked extensively with customers very early in the development phase and designed an instrument that could help smaller labs overcome the same productivity obstacles faced by larger labs,” said Cass Grandone, divisional vice president, Systems Development, Abbott Diagnostics. "The Architect i1000SR analyzer is ideal for facilities running less than 200 tests per day and offers productivity benefits, such as highly efficient sample processing, usually reserved for larger testing facilities. Since Architect utilizes common reagents, consumables, and software user interfaces, larger laboratories may be interested in using the instrument as a back-up system to the i2000SR.”

Similar to Architect ci8200 and ci16200, the analyzer is part of the Architect family, with important features including: family commonality, enhanced assay and system dynamics, and integration of immunoassay and clinical chemistry technologies without jeopardizing key performance, including turnaround time or accuracy of results.


Related Links:
Abbott

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.